Actuate Therapeutics Prices $11 Million Stock-and-Warrant Offering

Actuate Therapeutics priced an underwritten stock-and-warrant offering expected to raise about $11 million, giving the clinical-stage cancer drug developer financing for working capital and general corporate purposes if the sale closes. The offering covers 30,985,900 common shares and warrants to purchase up to 15,492,950 shares. Investors must buy the securities as a package of two shares and one warrant for $0.71, although the shares and warrants will be issued separately. The expected gross proceeds exclude underwriting discounts, commissions and other expenses. Each warrant allows its holder to buy a share for $0.45.

Source: TokenPost